UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) March 1118, 2014

HI-TECH PHARMACAL CO., INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
No. 0-20424	11-2638720
(Commission File Number)	(IRS Employer Identification No.)
369 Bayview Avenue, Amityville, New York	11701
(Address of Principal Executive Offices)	(Zip Code)
(631) 789-8228
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)

HI-TECH PHARMACAL CO., INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

No. 0-20424	11-2638720
(Commission File Number)	(IRS Employer Identification No.)

369 Bayview Avenue, Amityville, New York	11701
(Address of Principal Executive Offices)	(Zip Code)

(631) 789-8228

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 21.0201. ~~Results~~Entry ofinto ~~Operations~~a ~~and~~Material ~~Financial~~Definitive ~~Condition~~Agreement.

On March 11, 2014, Hi-Tech Pharmacal Co., Inc. (the “Company”), ECR Pharmaceutical Co., Inc. (“ECR”), a wholly owned subsidiary of the Company, ~~issued~~and Cameron Durrant entered into a ~~press~~separation agreement and general release ~~announcing~~(the ~~its~~“Separation ~~financial~~Agreement”). ~~results~~By ~~for~~its terms, the ~~third~~Separation ~~fiscal~~Agreement ~~quarter~~became ~~ended~~irrevocable ~~January~~and 31legally binding on March 18, 2014.

APursuant ~~copy~~to the Separation Agreement, the parties mutually agreed to a termination of Dr. Durrant’s employment with ECR effective March 13, 2014. Under the ~~press~~terms ~~release~~of the isSeparation ~~attached~~Agreement, as(i) ~~Exhibit~~Dr. 99Durrant will receive a severance payment in the amount of $550,000 (reduced for applicable deductions); (ii) Dr.1 Durrant will be entitled the continuation of certain health coverage benefits; (iii) Dr. Durrant will be entitled to ~~this~~retain all previously granted stock options, subject to certain other ~~current~~agreements; ~~report~~and (iv) Dr. Durrant will continue to be subject to certain restrictive covenants until March 13, 2015, and isindefinitely ~~incorporated~~in ~~herein~~the case of the non-use and non-disclosure of the Company’s and ECR’s confidential information. The parties also agreed to other customary terms and conditions including the return of property and the release of all claims against each other. The foregoing description of the Separtion Agreement is qualified by ~~reference~~the actual terms of the Separation Agreement, a copy of which is attached hereto as Exhibit 99.1.

~~The information in~~ Item 25.02 ~~and~~Departure ~~Item~~of ~~9.01~~Directors ~~shall~~or beCertain ~~deemed~~Officers; ~~to be~~Election ~~furnished~~of toDirectors; ~~the~~Appointment ~~Securities~~of ~~and~~Certain ~~Exchange~~Officers; ~~Commission~~Compensatory ~~but~~Arrangements ~~not filed and shall not be deemed incorporated by reference into any filings by the Company under the Securities Act~~ of ~~1933,~~Certain ~~as amended, unless the Company expressly states otherwise in such filing~~Officers.

As discussed in further detail in Item 91.01. above, ~~Financial~~the ~~Statements~~Company, ECR and ~~Exhibits~~Dr. Durrant mutually agreed to a termination of Dr. Durrant’s employment with ECR, effective at the close of business on March 13, 2014.

~~(d)~~Item 9.01 Financial Statements and Exhibits

~~The~~(d) ~~following exhibit is furnished herewith:~~Exhibits

Exhibit Number		Description
Exhibit No.		Description of Exhibit
Exhibit 99.1		Press Release of Hi-Tech Pharmacal Co., Inc.
99.1		Separation Agreement and General Release
		dated March 11, 2014

~~SIGNATURES~~2

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURES

Date: March 11, 2014	HI-TECH PHARMACAL CO., INC.
	/s/ William Peters
	Name: William Peters
	Title: Executive Vice President and Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 21, 2014	HI-TECH PHARMACAL CO., INC.

	/s/ David S. Seltzer
	Name: David S. Seltzer
	Title: President and Chief Executive Officer

~~INDEX TO EXHIBITS~~3

Exhibit Number		Description
99.1		Press Release of Hi-Tech Pharmacal Co., Inc. dated March 11, 2014

Exhibit 99.1 Separation Agreement and General Release

Filing Compare · HI TECH PHARMACAL CO INC